Peter Ordentlich - 01 Feb 2022 Form 4 Insider Report for Syndax Pharmaceuticals Inc (SNDX)

Role: Chief Scientific Officer
Signature: /s/ Michael A. Metzger, Attorney-in-Fact
Issuer symbol: SNDX
Transactions as of: 01 Feb 2022
Net transactions value: +$1,257,185
Form type: 4
Filing time: 03 Feb 2022, 16:32:14 UTC
Next filing: 26 Aug 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	SNDX	Common Stock	Other	$17,495	+1,412		$12.39	1,412	31 Jan 2022	Direct	F1
transaction	SNDX	Common Stock	Sale	$23,510	-1,412	-100%	$16.65	0	01 Feb 2022	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	SNDX	Stock Options (Right to buy)	Award	$1,263,200	+80,000		$15.79	80,000	02 Feb 2022	Common Stock	80,000	$15.79	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The Reporting Person is voluntarily filing this Form 4 to report the acquisition of 1,412 shares by the Reporting Person on 01/31/2022 pursuant to the Issuer's Employee Stock Purchase Plan.
F2	1/48th of the shares subject to the option shall vest monthly over a four-year period.